Philip Tønnesen1. 1. Department of Pulmonary Medicine, Gentofte University Hospital, Denmark. d144002@dadlnet.dk
Abstract
OBJECTIVES: To provide a short review of the evidence base supporting smoking cessation interventions, including behavioral therapy and pharmacological treatment options. METHODS: Published meta-analysis was mainly used supplemented with a limited literature search. RESULTS: Effective smoking cessation consists of pharmacotherapy and behavioral support. Counseling increases abstinence rates parallel to the intensity of support. First-line pharmacological drugs for smoking cessation are nicotine replacement products (patch, gum, inhaler, nasal spray, lozenge/tablets), varenicline and bupropion SR with scientific well-documented efficacy when used for 2-3 months and mostly mild side effects. Alternative therapies such as hypnosis and acupuncture have no scientifically proven effects. CONCLUSIONS: With the most optimal drugs and counseling today a 1-year abstinence rate of approximately 25% can be expected in smoking cessation. On-going research is examining the potential effects of nicotine vaccination as relapse prevention.
OBJECTIVES: To provide a short review of the evidence base supporting smoking cessation interventions, including behavioral therapy and pharmacological treatment options. METHODS: Published meta-analysis was mainly used supplemented with a limited literature search. RESULTS: Effective smoking cessation consists of pharmacotherapy and behavioral support. Counseling increases abstinence rates parallel to the intensity of support. First-line pharmacological drugs for smoking cessation are nicotine replacement products (patch, gum, inhaler, nasal spray, lozenge/tablets), varenicline and bupropion SR with scientific well-documented efficacy when used for 2-3 months and mostly mild side effects. Alternative therapies such as hypnosis and acupuncture have no scientifically proven effects. CONCLUSIONS: With the most optimal drugs and counseling today a 1-year abstinence rate of approximately 25% can be expected in smoking cessation. On-going research is examining the potential effects of nicotine vaccination as relapse prevention.
Authors: Arthur L Brody; Todd Zorick; Robert Hubert; Gerhard S Hellemann; Shabnam Balali; Sarah S Kawasaki; Lizette Y Garcia; Ryutaro Enoki; Paul Abraham; Paulina Young; Charles McCreary Journal: Nicotine Tob Res Date: 2016-08-03 Impact factor: 4.244
Authors: Irina Esterlis; Effie M Mitsis; Jeffery C Batis; Frederic Bois; Marina R Picciotto; Stephanie M Stiklus; Tracy Kloczynski; Edward Perry; John P Seibyl; Sherry McKee; Julie K Staley; Kelly P Cosgrove Journal: Int J Neuropsychopharmacol Date: 2010-10-29 Impact factor: 5.176
Authors: Anthony L Zhang; Yuan Ming Di; Christopher Worsnop; Brian H May; Cliff Da Costa; Charlie C L Xue Journal: Evid Based Complement Alternat Med Date: 2013-09-28 Impact factor: 2.629